Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 17/20 | 0.59 |
| ▸ | JAK2 | O60674 | 8/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | LYN | P07948 | 1/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | TYK2 | P29597 | 1/20 | 0.59 |
| ▸ | TEC | P42680 | 1/20 | 0.59 |
| ▸ | TXK | P42681 | 1/20 | 0.59 |
| ▸ | BMX | P51813 | 1/20 | 0.59 |
| ▸ | ITK | Q08881 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27982129 | 0.91 | BTK (0.60) | BTKJAK2AURKALCKLYN | |
| SCHEMBL27982558 | 0.89 | BTK (0.71) | BTKJAK2AURKALCKLYN | |
| SCHEMBL27982591 | 0.85 | BTK (0.62) | BTKJAK2AURKALCKLYN | |
| SCHEMBL123345 | 0.83 | BTK (0.80) | BTKJAK2AURKALCKLYN | |
| SCHEMBL122351 | 0.83 | BTK (0.63) | BTKJAK2AURKALCKLYN | |
| SCHEMBL124432 | 0.81 | BTK (0.59) | BTKJAK2AURKALCKLYN | |
| SCHEMBL27982139 | 0.80 | BTK (0.57) | BTKJAK2AURKALCKLYN | |
| SCHEMBL124441 | 0.77 | BTK (0.67) | BTKJAK2AURKALCKLYN | |
| SCHEMBL122358 | 0.77 | BTK (0.67) | BTKJAK2AURKALCKLYN | |
| SCHEMBL123407 | 0.77 | BTK (0.74) | BTKJAK2AURKALCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102325753-B | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2014-09-10 | — | — | CN | claimed |
| EP-2391602-B1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-04 | — | — | EP | claimed |
| CN-102325753-B | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2014-09-10 | — | — | CN | disclosed |
| EP-2391602-B1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| CN-102325753-A | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2012-01-18 | — | — | CN | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2391602-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010080481-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | BTK 1/4885JAK2 13/4885AURKA 248/4885 |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | BTK 1/4885JAK2 13/4885AURKA 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.